and MRTX1719 (MTA-cooperative PRMT5 inhibitor). Prior to Mirati, he served as head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback